awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41807279-15E443A0-5593-484B-BFEE-B91479052255
Q41807279-15E443A0-5593-484B-BFEE-B91479052255
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41807279-15E443A0-5593-484B-BFEE-B91479052255
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
P2860
Q41807279-15E443A0-5593-484B-BFEE-B91479052255
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41807279-15E443A0-5593-484B-BFEE-B91479052255
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6eea7fe1f0d7ce23047ade29a0743353a4a18438
P2860
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.